Agios Reports Q1 2026 Earnings Results with Strong Revenue Growth
Agios (AGIO) reported Q1 2026 earnings with net revenues of $20.7 million, a 138% increase year-over-year, driven by the commercial launch of AQVESME in thalassemia. The company also highlighted strong liquidity, with over $1 billion in cash and marketable securities, and outlined regulatory and pipeline progress for mitapivat and tebapivat.
Tickers: $AGIO
Topics: AQVESME launch earnings mitapivat R&D expenses regulatory updates revenue